Form 4: Royalty Pharma EVP & CFO Terrance P. Coyne Reports Acquisition of Class E Ordinary Shares

Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, reports the indirect acquisition of Class E ordinary shares in Royalty Pharma Holdings Ltd pursuant to a Membership Interests Purchase Agreement.

Summary

• Terrance P. Coyne, the EVP & CFO of Royalty Pharma plc, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates an indirect acquisition of 1,807,277 Class E ordinary shares of Royalty Pharma Holdings Ltd (RPH).
• This acquisition is related to the Membership Interests Purchase Agreement dated January 10, 2025, between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer, and other parties.
• The Class E shares vest in installments over a 9-year period.
• Once vested, each Class E share can be converted into one Class B ordinary share of RPH, which can then be converted into one Class A ordinary share of Royalty Pharma plc.
• There is no expiration date for these conversions.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to executive compensation. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Future Outlook

The Class E shares will vest over a 9-year period, implying a long-term incentive structure for the reporting person.

Industry Context

This filing reflects standard executive compensation practices within publicly traded companies, where equity-based awards are used to align management's interests with those of shareholders.

Stakeholder Impact

• The acquisition of Class E shares by the CFO aligns his interests with those of the shareholders, incentivizing long-term value creation.

Key Dates

Keywords

Royalty Pharma, Terrance P. Coyne, Class E Ordinary Shares, Beneficial Ownership, Form 4, RPRX, RPH, Membership Interests Purchase Agreement